Microbiology Independent Research Journal (MIR Journal)

MIR Journal is an international resource for academic researchers in virology, bacteriology, and mycology as well as for professionals in the pharmaceutical and biopharmaceutical industry. 


Microbiology Independent Research Journal (MIR Journal)

ISSN 2500-2236

MIR Journal is indexed in 22 databases, including DOAJ, Chemical Abstracts, EBSCO, CORE, Google Scholar, and eLibrary.ru.


MIR Journal is an international resource for academic researchers in virology, bacteriology, and mycology as well as for professionals in the pharmaceutical and biopharmaceutical industry. 

MIR Journal publishes strictly peer-review papers. MIR Journal publishes the following categories of scientific papers:

  • Editorials
  • Hypotheses
  • Research Articles
  • Short Communications
  • Reviews, including mini-reviews
  • Commentaries

Publication in MIR Journal is free of charge for all the authors.


Aim & Scope

MIR Journal covers a wide range of topics including: theory and practice of new vaccine development; vaccines against new emerging viruses; development of universal vaccines (influenza) and viral vector-based vaccines; mechanisms of viral attenuation; vaccine production technology; antiviral and antimicrobial drug discovery; results of clinical studies; the study of new drug targets for viruses and bacteria; new plasmid-based vectors and their application in biotechnology; synthesis, biosynthesis, structure and function of biomolecules critical for the life cycle of prokaryotes and viruses. MIR Journal includes manuscripts on bacterial synthetic biology, bacterial mutations and antibiotic resistance as well as on new approaches and methods of antiviral and antimicrobial defense.

The devastating COVID 19 pandemic and spread of bacterial antibiotic resistance in recent years moved virology and bacteriology to the forefront of medical science in healthcare. Infectious agents do not recognize country borders and close worldwide cooperation between scientists and medical personnel is necessary to prevent the spread of dangerous pathogens. The main objective of the MIR Journal is to provide broad international coverage of scientific results in virology, bacteriology, and mycology and to extend the accessibility of these results to a worldwide scientific audience.



Publishing Policy


Microbiology Independent Research Journal (MIR Journal) is an open access journal. All articles are made freely available to readers immediatly upon publication.

Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition - it means that articles have free availability on the public internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from gaining access to the internet itself.

For more information, please read BOAI statement.



Information for Authors & Copyright Notice


Copyright Notice

The authors who publish papers in this journal agree to the following:

The authors retain the copyright for the paper and grant the journal the right to first publish the paper under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License (CC BY-NC-SA), which permits unrestricted use, distribution, and reproduction in any medium, as long as the material is not used for commercial purposes, provided that the original author and source are cited.


Preprint and post print Policy

The editorial board of the MIR Journal allows authors to post the manuscript as a preprint on preprint servers and in disciplinary and institutional repositories before submission for review and to archive independently their accepted for publication articles in disciplinary and institutional repositories as well as to disseminate through a personal website or blog.



The editorial board of the MIR Journal encourages uploading preprints of the submitted manuscripts on preprint servers. The Committee on Publication Ethics (COPE) defines a preprint as “a scholarly manuscript posted by the author(s) in an openly accessible platform, usually before or in parallel with the peer review process.” 

A preprint publication should not be considered a duplicate publication, nor shall it influence the editor's decision to publish the manuscript in the MIR Journal.

The author should notify the editorial board of the MIR Journal about the posted preprint at submission of the manuscript for review, furnishing a link to the preprint with its DOI identifier and the dissemination terms and conditions.

It is the author’s responsibility to add a link to the published manuscript in the preprint record. The link must contain the DOI, and the URL of the article published on the journal's website. The original preprint should not be modified based on the reviewer’s and editor’s comments. The preprint should not be replaced with the text of the published article. The preprint text should not be deleted.


Manuscripts Accepted for Publication

The authors can independently archive their manuscripts that have been reviewed and are accepted for publication in MIR Journal.

 This version of the manuscript may be disseminated through:

  • personal website or blog;
  • institutional repository;
  • disciplinary repository;
  • direct interactions with faculty or students by providing this version of the manuscript for personal use.

The text of the manuscript should contain the author’s clarifications about its status and information about the planned publication.

Example: The article “TITLE” has been reviewed, accepted for publication, and will be published in 2021 (3) of the MIR Journal.

Once the final version of the manuscript is published, it is the author’s responsibility to add a link to the published article to the publication record. The posted text should not be modified based on the reviewer’s and editor’s comments. The text of the posted manuscript should not be replaced or deleted. 


Final Versions of Manuscripts

The editorial board of MIR Journal allows for the independent archival of the manuscripts that have been peer-reviewed, accepted for publication, edited and ready for publication (proofread and typeset). This version of the manuscript may be disseminated through:

  • personal website or blog;
  • institutional repository;
  • disciplinary repository;
  • direct interactions with faculty or students by providing this version of the manuscript for personal use.

Once the final version of the manuscript is published, it is the author’s responsibility to add a link to the published article to the publication record. The posted text should not be modified based on the reviewer’s and editor’s comments. The text of the posted manuscript should not be replaced or deleted.

The authors reserve the right to enter into separate contractual agreements regarding the non-exclusive distribution of the version of the paper published in MIR Journal (for example, placing it in the institution's repository, publication in a book), with the reference to its original publication in this journal.


Privacy Statement

All the personal data disclosed when submitting the manuscript for publication (e.g., names, addresses, e-mail addresses, job titles, and affiliation) will be used solely for technical purposes of a contact with the authors and reviewers (editors) when preparing the article for publication. Personal data will not be shared with other individuals and organizations.


Plagiarism detection

MIR Journal uses Ithenticate software to screen the submitted manuscripts for plagiarism. If plagiarism is identified, the COPE guidelines on plagiarism will be followed.



Author Guidelines


The guidelines for authors are based on the CSE's recommendations on Promotion of Integrity in Scientific Journal Publications https://www.councilscienceeditors.org/recommendations-for-promoting-integrity-in-scientific-journal-publications and ICMJE Recommendations for the conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals https://www.icmje.org/recommendations/.   

The editorial board of MIR Journal is committed to promoting wide international coverage of advances in microbiology and increasing the availability of published materials. To achieve this goal, all articles are published in English and are available in open access on the journal’s website.

The journal accepts manuscripts from graduate students, Ph.D. students, scientists, and experts in the fields of virology, bacteriology, mycology, and drug discovery.




Submission of a manuscript for publication to the MIR Journal implies that:

  • the article has not been previously published in another journal;
  • the article is not under consideration in another journal;
  • all co-authors agree with the publication of the current version of the article.

Before submitting a manuscript for publication make sure that the file(s) contains all the necessary information, that the sources of all the data presented in the figures and tables are referenced, and that all references are given in the correct format.

The manuscript must be accompanied by permission to reproduce previously published material and to use previously published illustrations.

The editors of the MIR Journal recommend authors to use the following requirements and guidelines developed by international health organizations:



Language policy

Articles should be submitted in English (in American spelling) or Russian. All articles are assigned a DOI index and posted on the journal website in open access.


Letter to the editor

The article submitted to the journal must be accompanied by a letter to the editor, which should reflect the following aspects:

  • The manuscript corresponds to the scope of the MIR Journal.
  • All authors agree with the publication and approve the manuscript.
  • The results have not been published elsewhere and the manuscript has not been submitted to another journal.
  • Conflict of Interest Statement: Authors are solely responsible for resolving all financial conflicts between themselves or with any third party.


Article types

The journal accepts for publication editorial articles, original research articles, short communications, reviews, mini-reviews, case studies and reports, clinical trials reports, hypotheses, and comments.


The research article should describe completed research study and include the following sections: Abstract, Introduction, Materials and Methods, Results, Discussion, Acknowledgments, Conflict of Interest, Keywords, Funding, and References. The research article should not exceed 7000 words, including a list of references, tables, and figure captions.

The short communication should briefly describe a completed study and include the following sections: Introduction, Materials and Methods, Results and Discussion, Acknowledgments, Conflict of Interest, Keywords, Funding, and References. The short communication should not exceed 3000 words, including a list of references, tables, and figure captions.

Reviews are published by invitation of the editorial board or by the initiative of the author. The maximum volume of the review corresponds to the maximum volume of the research article.


Article format

Manuscripts submitted to the MIR Journal must be in the format approved by the editorial board.

For details on the language of the publication, see the Language Policy section. The text including the names of tables and figures and captions under the tables and figures should be written using the 12 points Times New Roman font with two-line spacing.

Pages should be A4 (210 x 297 mm) format. All the symbols that are used in the manuscript should be available in Microsoft Office Word documents. All pages, including the first one, should be numbered. Tables and figures captions should correspond to the references to them.

Figures and Tables as well as figure captions should be placed right after the corresponding reference in the text. Additionally, when submitting the manuscript, all figures should be submitted as separate files in TIFF or EPS format with minimum resolution 300 dpi. Tables should be placed in the text of the manuscript, numbered with Arabic numbers and accompanied by appropriate headings.


The title of each subsection should be in bold.

It is recommended to use the past tense to describe the results. Generally accepted facts and conclusions should be written in the present tense.


The manuscript should contain the following sections:

i. Title Page

The following should be placed on the title page of the article:


a. Article title

The title should fully correspond to the essence of the research study described in the article.

Additionally, it is necessary to provide the short title (no more than 50 characters).


b. Name(s) of the author(s)

Authors are individuals identified by the research team as key contributors to the work presented in the manuscript and who have agreed to take responsibility for their work. In addition to being responsible for his/her part of the work, the author should be able to point out who from his co-authors is responsible for other parts of the work.

The activities that prevent a research participant from being recognized as an author of the manuscript include search for the project funding, general leadership of the research team, general administrative support, assistance in the manuscript writing, technical editing, scientific editing and proofreading of the manuscript. An author identified as a corresponding author is responsible for obtaining written permission from all contributors mentioned in the Acknowledgments section.

If, after accepting the manuscript for publication, it becomes necessary to change the list of the authors, a letter should be sent to the editorial board of the journal with an explanation of the reason for this change. The main responsibility for the exchange of information with the journal’s editorial board in the process of submitting, reviewing, and publishing an article lies on the corresponding author. The corresponding author is responsible for submitting all required documents, including ethics committee approval, clinical trial registration documents, and conflict of interest statements. The corresponding author is also responsible for responding in a timely manner to critical comments on the article that arise after its publication.

The MIR Journal accepts the following criteria for authorship:

  1. Substantial contributions to study design and experimental design, data collection, or data analysis and interpretation.
  2. Preparation of an article or its critical revision in terms of meaningful intellectual content.
  3. Final approval of the version of the article for publication.

The list of authors does not include persons who are not the authors of the article. The names of individuals who are not the authors, but provided other support, are listed in the Acknowledgments section.

When listing the authors of the article, first name comes first, then the middle name initial (when available) follows, followed the last name/surname (Peter S. Ivanov). The last name in English should be written using the spelling used in previously published papers in English. If the author does not have any publications, the BSI standard must be used to transliterate the first and last names.


c. Information about the author(s)

This section lists titles, positions, degrees, and ORCID numbers with links to the site https://orcid.org/. It also contains the e-mail and full postal address of the corresponding author, with whom members of the editorial board can correspond. The name of this author should be marked with a sign (#).


d. Affiliation of the author(s)

Affiliation includes the following: full official name of the organization, full postal address (including postal code, city, and country). Authors are required to list all the workplaces related to conducting the research study.

If authors from different institutions participated in the preparation of the article, it is necessary to indicate the affiliation of each author to a specific institution using a superscript index.


ii. Abstract

The article is accompanied by an Abstract. The Abstract of the paper must reflect its main content and cannot exceed 250 words. The Abstract should be clear, complete and contain the main findings of the study. The abstract should be structured and include the following sections: INTRODUCTION, OBJECTIVE, METHODS, RESULTS, CONCLUSION. Sections are formatted in separate paragraphs without indentation, their headings are indicated at the beginning of the corresponding paragraph in bold capital letters with a colon after it. Review articles and meta-analyses require an abstract with the following headings: OBJECTIVES, DATA SOUCES, DATA SYNTHESIS, CONCLUSION, and KEYWORDS.


iii. Keywords

5-7 words corresponding to the topic of the article. It is desirable that the keywords complement the abstract and title of the article.


iv. Acknowledgments

In this section, all sources of funding for the study are listed. Also, in this section, thanks are given to the persons who participated in the research study described in the article and in the preparation of the manuscript but are not the authors of the article. This implies such activities as recommendations for improving the research, providing space for research, departmental control, obtaining financial support, conducting certain types of analysis, providing reagents / patients / animals / other materials for the research as well as assistance in the manuscript writing, technical editing, scientific editing and proofreading of the manuscript.


v. Conflict of interest

Conflicts of interest are conditions that lead to authors having conflicting or competing interests that can influence their editorial decisions. Conflicts of interest can be potential or perceived, as well as real. Personal, political, financial, scientific, or religious factors can influence the objectivity of the assessment of the conflict.

A conflict of interest arises when professional judgment is influenced by financial gain. Financial benefits may include, but are not limited to, employment, consulting, shareholding and additional opportunities, royalties, patents, paid expertise, etc. Authors should avoid entering into agreements with research project sponsors that prevent access to any research data or the ability to analyze and interpret the data.

Authors of submitted manuscript are responsible for disclosing any financial and personal relationships that may cause any conflict of interest. Authors should describe sources of support for the project, including the names of sponsors and their role in planning the study, as well as in collecting, analyzing, and interpreting data and writing the manuscript. If the personnel of the supporting organizations are not involved in the research process, then a corresponding statement should be provided.

The corresponding author should sign the Conflict of Interest Disclosure Form developed by the International Committee of Medical Journal Editors ICMJE http://www.icmje.org/disclosure-of-interest/.

The authors are obliged to notify the editor of a real or potential conflict of interest by including information about the conflict of interest in the appropriate section of the article.

If there is no conflict of interest, the author should also declare this. An example of the wording for this declaration: "The author declares no conflicts of interest."


vi. Article text

The journal adopted the IMRAD format (Introduction, Materials and Methods, Results, Discussion)


a. Introduction. The Introduction section should contain background information on the problem under study. At the end of the Introduction, a working hypothesis or purpose of the research study should be stated. Research findings should not be included in the Introduction section.


b. Materials and Methods. In the Materials and Methods section all materials, methods and experimental conditions used in the research study should be described so that they can be reproduced by other scientists. If the method is known and has been described in other publications, then a reference on the published method description should be provided. If the previously published method has been modified, all the changes should be described in detail. The name, purity, and manufacturer of all reagents as well as the name and manufacturer of the equipment should be given. When describing centrifugation conditions, centrifuge model, rotor model and acceleration (g) should be given. All microbial and viral strains used in the study should be named according to the currently used and internationally accepted taxonomic classification system. All chemicals should be named according to the rules of nomenclature of the International Union of Pure and Applied Chemistry (IUPAC). If the article describes any animal experiments or clinical studies involving humans, then all appropriate approvals should be given. The date of issue and the registration number for the approval of the study by the local ethics committee should also be given in the Materials and Methods section.


c. Results. All experimentally discovered facts should be given in the Results section. This section may contain subsections according to the study design. The number of repetitions of the experiments, the number of replicas or the number of animals at each time point should be given.

A complete statistical analysis should be submitted, including the used software and the likelihood. Extensive interpretation and discussion of the results should be avoided in this section. All tables and figures should be numbered and the references to them should be given in the text.


d. Discussion. The main topic of discussion is the interpretation of the results in accordance with the latest published data. Duplication of results in the Discussion section should be avoided. In Short Communications the results and discussion should be combined in one section (Results and Discussion).


e. References.  The journal uses the Vancouver citation format, which implies a reference to the source in square brackets in the order of their appearance in the text and the subsequent description of sources in the References section in the same order.

References should be written according to the "Samples of Formatted References for Authors of Journal Articles" available at https://www.nlm.nih.gov/bsd/uniform_requirements.html.

For publications that have a Digital Object Identifier (DOI), it is mandatory to include this identifier in the description of the source with a link to the site https://www.doi.org/.

The References section should include only peer-reviewed sources mentioned in the text - articles from scientific journals, books, book sections and patents. References to textbooks, teaching aids, statistical reports, articles in newspapers and magazines, dissertations (if it is not possible to cite the articles published as a result of the corresponding research), and author's comments should be given in footnotes (see the Footnotes section below) and should not be included in the References section. The references on web documents, conference papers and proceedings, personal communications and state standards are placed in the text of article in brackets and should not be included in the References section. Internet links are provided as a complete URL. The authors of the manuscript should site personal communication only if it provides essential information not available from the public source. In this case written permission and confirmation of accuracy should be obtained from the source of a personal communication. The description of the sources in the References section should contain the names of all authors with their initials, the title of the article, the abbreviation of the journal, year, volume, first and last page, and DOI. If there are more than six authors, the names of the first six authors should be given followed by "et al.". The titles of journals should be abbreviated according to the style used for MEDLINE (www.ncbi.nlm.nih.gov/nlmcatalog/journals).

References to manuscripts that have been submitted for publication but have not been accepted for publication yet should be given in the text and indicated as unpublished data with written permission from the source and should not be included in the References section. The References section should not contain any text in italics or bold. References to Russian sources are provided both in Russian and in English translation.

Below are some examples of the references:



  1. Collins PL, Wertz GW. cDNA cloning and transcriptional mapping of nine polyadenylylated RNAs encoded by the genome of human respiratory syncytial virus. Proc Natl Acad Sci U S A. 1983;80(11):3208-12. https://doi.org/10.1073/pnas.80.11.3208.
  2. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med. 2000;161(5):1501-7. http://www.doi.org/10.1164/ajrccm.161.5.9906076.
  3. Цыганова ЕВ, Глухоедова НВ, Жиленкова АС, Федосеева ТИ, Ющук ЕН, Сметнева НС. COVID-19 и особенности вовлечения сердечно-сосудистой системы. Терапевтический архив. 2021;93(9):1091-9. http://www.doi.org/10.26442/00403660.2021.09.201036.

    Tsyganova EV, Glukhoedova NV, Zhilenkova AS, Fedoseeva TI, Iushchuk EN, Smetneva NS. COVID-19 and features of cardiovascular involvement. Terapevticheskii Arkhiv (Ter Arkh). 2021;93(9):1091-9. (In Russian). http://www.doi.org/10.26442/00403660.2021.09.201036.



Recommended composition of influenza virus vaccines for use in the 2012-2013 Northern hemisphere influenza season https://www.who.int/publications/m/item/recommended-composition-of-influenza-virus-vaccines-for-use-in-the-2023-2024-northern-hemisphere-influenza-season [24 February 2023].



Bates B. Bargaining for life: A social history of tuberculosis. 1st ed. Philadelphia: University of Pennsylvania Press; 1992.


Chapters from books

Lindenbach BD, Murray CL, Thiel H-J, Rice CM. Flaviviridae: The Viruses and Their Replication. In: D. M. Knipe et al. editors. Fields Virology. 6th ed. Lippincott Williams & Wilkins, New York, NY. 2013. Chapter 25. p. 712-746.


Drawings and other illustrations

MIR Journal accepts uncompressed high-resolution images in black and white or color composed of lines and text in TIFF or EPS format (900-1200 dpi); photographs, which contains no text in TIFF (300 dpi); images containing halftone and text or line art elements in TIFF, and EPS formats (500-900 dpi). The minimum resolution is 300 dpi. More detailed instructions on formatting graphic images can be found on the website: : https://www.ncbi.nlm.nih.gov/pmc/pub/filespec-images/#fig-format.

References to figures should be given as follows: “In Fig. 3 it is shown that ... “or“ It is shown that ... (Fig. 3)”. If there is only one figure in the text, then it should not be numbered.

Each figure must be accompanied by a title and a separate caption that discloses the content of the figure, so that there is no need to refer to the Materials and Methods section. All symbols on the picture should be explained in the caption to it. When submitting the manuscript, the figures should be included in the main text and also should be submitted as separate files in TIFF or EPS format with minimum resolution 300 dpi. It is recommended to use only one type of font for each illustration. Graphic files should not contain wide margins.



Footnotes are numbered in Arabic numerals and placed page by page. Footnotes may contain references to textbooks, teaching aids, statistical reports, articles in newspapers and magazines, dissertations (if it is not possible to cite the articles published as a result of the corresponding research), and author's comments. References on all these sources of information are not included in the References section.



Tables should be placed in the text of the manuscript, numbered with Arabic numbers, and accompanied by appropriate headings. Column headings should be as concise as possible. Tables created in Microsoft Excel are not accepted; they must be in the Microsoft Word format. The table can contain notes marked with superscript letter indexes (for example: a, b, c ...).

Explanations for each letter index should be placed below the table. If there is only one table in the text, then it should not be numbered. The table grid should consist of the minimum required number of lines: there are no vertical lines, horizontal lines separate column and section headings.


Proteins, amino acid sequences, or nucleotide sequences

All new protein or nucleotide sequences presented in the manuscript must be submitted to one of the international depositories and have the corresponding registration number. In the manuscript such sequences should be presented as figures.


Supporting information

The essential supporting files and multimedia files can be submitted along with the manuscript, which will be subject to peer review.


Abbreviations and Symbols 

Authors should use only standard abbreviations and avoid them in the title of the manuscript. The full name followed by the abbreviation in parentheses should be used on first mention.


Units of Measurement 

Measurements should be reported in metric units (e. g. meter, kilogram, second or liter) or their decimal multiples. Temperatures should be in degrees Celsius; pressures - in millimeters of mercury.




The manuscript should be submitted through the submission system of the ScienceOpen after pre-registration on the site: https://www.scienceopen.com/collection/f76a296c-da60-422b-9200-f50119a511ba/upload-preprint?4.

The manuscript that is initially uploaded to the website for the peer review should be in the pdf format. After the manuscript is accepted for publication, it should be uploaded to the website in the Microsoft Word format (have the ‘docx’ extension). Text should be typed with an interval of two-line spacing, font Times New Roman, 12 pt; to highlight the accents it is recommended to use italics rather than underlining (except Internet links). All images, graphics, and tables are placed within the text of the manuscript and also are uploaded as separate files.  




 The editorial office of the journal maintains correspondence with the corresponding author, however, e-mail messages could be sent to all authors who have their e-mail addresses listed in the manuscript, if the team of authors wishes to do so. All manuscripts submitted to MIR Journal are pre-checked by the executive secretary of the journal for compliance with formal requirements. At this stage, the manuscript could be returned to the author(s) for revision with a request to correct errors or add missing data. Also at this stage, the manuscript may be rejected due to mismatch with the scope of the journal, lack of originality, and low scientific value.

After a preliminary check, the editor-in-chief submits the article to the reviewers, setting up the time frame of the review. In controversial cases, several specialists as well as the editor-in-chief could be involved in the peer review process.

After at least two positive reviews are received for the manuscript, it is passed to the editor for the preparation for publication.

When it is necessary to revise the manuscript, all the comments and commentaries of the reviewers are sent to the corresponding author. The authors are given 2-4 weeks to revise the manuscript. If during this period the authors have not notified the editorial office of the planned actions, the manuscript could be removed from the queue for publication.

When a decision is made to decline the manuscript publication, the decision of editor-in-chief is sent to the corresponding author.

If the manuscript is accepted for publication, the final version of the manuscript layout is sent to the corresponding author for review. A response is expected from the corresponding author within 2 days. In the absence of a response from the corresponding author, the layout of the manuscript is considered approved.




If the author(s) does not agree with the conclusion of the reviewer and/or editor or with their particular comments, he/she can challenge the decision. To do this, the author needs:

  • correct the manuscript according to reasonable comments from the reviewers and editors;
  • clearly state his/her position on the issues in dispute.

The editors promote resubmission of manuscripts that could potentially be accepted but were rejected due to the need for significant changes or additional data collection and are ready to explain in detail to the corresponding author what needs to be corrected in the manuscript in order for it to be accepted for publication.




In case of revelation of unfair behavior on the part of the author(s), detection of plagiarism, fabrication or falsification of data, the editors proceed according to the COPE rules.

By unfair behavior, MIR Journal recognizes any actions of a scientist, including improper handling of objects of study or deliberate manipulation of scientific information, that lead to incorrect observation of phenomena and wrong conclusions, as well as the behavior of a scientist that does not meet accepted ethical and scientific standards.

MIR Journal does not classify as unfair conduct the honest error or honest discrepancy in the design, conduct of experiments, interpretation, or evaluation of research methods or results, or any unfair conduct not related to the scientific process.




If errors are found in the text of the published article that affect its perception, but do not distort the stated research results, they can be corrected by replacing the PDF file of the article and indicating the error in the article file itself and on the corresponding page on the journal website.

If errors are found in the text of the article that distort the results of the research, or in the case of plagiarism, the discovery of unfair behavior of the author(s) associated with falsification and/or fabrication of data, the article may be withdrawn. The retraction of an article can be initiated by the editorial board, the author, an organization, or an individual.

The withdrawn article is marked with the sign "Article withdrawn", the information about the reason for the withdrawal of the article is published on the article webpage. Information about the retraction of the article is sent to the databases in which the journal is indexed.


Submission Preparation Checklist

As part of the submission process, authors are required to check off their submission's compliance with all of the following items, and submissions may be returned to authors that do not adhere to these guidelines.

  1. The manuscripts are accepted if it has not been published or submitted for publication elsewhere.
  2. The materials should be prepared in pdf format for the initial submission and in the Microsoft Word format for the final submission.
  3. Internet links are provided as a complete URL. 
  4. The text should be typed with an interval of two-line spacing, font Times New Roman, 12 pt; to highlight the accents, it is recommended to use italics rather than underlining (except Internet links). All images, graphics, and tables are placed within the text of the manuscript and also are uploaded as separate files.
  5. Bibliography requirements as stated in the Reference section above.





Editorial Board



Scientific activities

1989 Ph.D. Thesis defended (Virology)

Postdoctoral Training

1992 Royal Medical University, Newcastle, Australia

1994 Influenza Branch, Centers for Disease Control (CDC), Atlanta, Georgia, USA,

1995-2006 Institute of Applied Microbiology, University of Natural Resources and Life Sciences, Vienna, Austria

2006-2012 Green Hills Biotechnology AG, Vienna, Austria

2012 Habilitation Thesis defended (Virology)

2014-2015 HSC Development GmbH, Tulln, Austria

2016 - current EURRUS GmbH, Tulln, Austria

List of most relevant publications of Romanova J (Romejko-Gurko J)


  1. Romanova J, Rydlovskaya A, Mochalov S, Proskurina O, Gorokh Y, Nebolsin V. The Effect of Anti-Chemokine Oral Drug XC8 on Cough Triggered by The Agonists of TRPA1 But Not TRPV1 Channels in Guinea Pigs. Pulm Ther. 2022 Mar;8(1):105-122.
  2. Romanova J, Chikina E, Rydlovskaya A, Pohl W, Renner A, Zeifman A, Chuchalin A, Nebolsin V. New Anti-Chemokine Oral Drug XC8 in the Treatment of Asthma Patients with Poor Response to Corticosteroids: Results of a Phase 2A Randomized Controlled Clinical Trial. Pulm Ther. 2020 Dec;6(2):351-369. 
  3. Ferko B, Romanova J, Rydlovskaya AV, Kromova TA, Proskurina OV, Amelina AN, Schmutz H, Renner A, Nebolsin VE. A Novel Oral Glutarimide Derivative XC8 Suppresses Sephadex-Induced Lung Inflammation in Rats and Ovalbumin-induced Acute and Chronic Asthma in Guinea Pigs. Curr Pharm Biotechnol. 2019;20(2):146-156. 
  4. Renner A, Romanova J, Ferko B, Schmutz H, Nebolsin V, Müller M, Badorrek P, Marth K, Pohl W. Safety, pharmacokinetics and pharmacodynamics of a novel anti-asthmatic drug, XC8, in healthy probands. Pulm Pharmacol Ther. 2019 Dec;59:101852.
  5. Kittel C, Wressnigg N, Shurygina AP, Wolschek M, Stukova M, Romanovskaya-Romanko E,Romanova J, Kiselev O, Muster T, Egorov A. A genetically adjuvanted influenza B virus vector increases immunogenicity and protective efficacy in mice. Arch Virol. 2015 Oct;160(10):2525-34.
  6. Sansyzbay AR, Erofeeva MK, Khairullin BM, Sandybayev NT, Kydyrbayev ZK, Mamadaliyev SM, Kassenov MM, Sergeeva MV, Romanova JR, Krivitskaya VZ, Kiselev OI, Stukova MA. Inactivated and adjuvanted whole virion clade 2.2 H5N1 (A/chicken/Astana/6/05) influenza vaccine is safe and immunogenic in a single dose in humans. Clin Vaccine Immunol. 2013 Aug;20(8):1314-9.
  7. Morokutti A, Rediberger-Fritz M, Nakowitsch S, Krenn BM, Wressnigg N, Jungbauer A, Romanova J, Muster T, Popow-Kraupp T, Ferko B. Validation of the modified hemagglutination assay (mHAI), a robust and sensitive serological test for analysis of influenza virus-specific immune response. 2013 J clin Virol. 56(4) 323-30.
  8. Nakowitsch S, Waltenberger AM, Wressnigg N, Ferstl N, Triendl A, Kiefmann B, Montomoli E, Lapini G, Sergeeva M, Muster T, Romanova JR. Egg- or cell culture-derived hemagglutinin mutations impair virus stability and antigen content of inactivated influenza vaccines. Biotechnol J. 2014 Mar;9(3):405-14.
  9. Roethl E, Gassner M, Krenn BM, Romanovskaya-Romanko EA, Seper H, Romanova J, Nakowitsch S, Sturlan S, Wolschek M, Sirotkin A, Kiselev O, Muster T, Egorov A. Antimycotic-antibiotic amphotericin B promotes influenza virus replication in cell culture. 2011 J Virol. 2011, 85, 21.
  10. Nakowitsch S, Wolschek M, Morokutti A, Ruthsatz T, Krenn BM, Ferko B, Ferstl N, Triendl A, Muster T, Egorov A, Romanova J. Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1.Vaccine. 2011 Apr 27;29(19):3517-24.
  11. Krenn BM, Egorov A, Romanovskaya-Romanko E, Wolschek M, Nakowitsch S, Ruthsatz T, Kiefmann B, Morokutti A, Humer J, Geiler J, Cinatl J, Michaelis M, Wressnigg N, Sturlan S, Ferko B, Batishchev OV, Indenbom AV, Zhu R, Kastner M, Hinterdorfer P, Kiselev O, Muster T, Romanova J. Single HA2 mutation increases the infectivity and immunogenicity of a live attenuated H5N1 intranasal influenza vaccine candidate lacking NS1. PLoS One. 2011 Apr 7;6(4):e18577.
  12. Wacheck V, Egorov A, Groiss F, Pfeiffer A, Fuereder T, Hoeflmayer D, Kundi M, Popow-Kraupp T, Redlberger-Fritz M, Mueller CA, Cinatl J, Michaelis M, Geiler J, Bergmann M, Romanova J, Roethl E, Morokutti A, Wolschek M, Ferko B, Seipelt J, Dick-Gudenus R, Muster T. A novel type of influenza vaccine: safety and immunogenicity of replication- deficient influenza virus created by deletion of the interferon antagonist NS1.J Infect Dis. 2010 Feb 1;201 (3):354-62.
  13. Romanova J, Krenn BM, Wolschek M, Ferko B, Romanovskaja-Romanko E, Morokutti A, Shurygina AP, Nakowitsch S, Ruthsatz T, Kiefmann B, König U, Bergmann M, Sachet M, Balasingam S, Mann A, Oxford J, Slais M, Kiselev O, Muster T, Egorov A. Preclinical evaluation of a replication-deficient intranasal DeltaNS1 H5N1 influenza vaccine.PLoS One. 2009 Jun 19;4(6):e5984.
  14. Romanova J. The fight against new types of influenza virus. Biotechnol J. 2006 Dec;1(12):1381-92. Review.
  15. Wressnigg N, Voss D, Wolff T, Romanova J, Ruthsatz T, Mayerhofer I, Reiter M, Nakowitsch S, Humer J, Morokutti A, Muster T, Egorov A, Kittel C. Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate. Vaccine. 2009 May 11;27(21):2851-7.
  16. Fischlechner M, Reibetanz U, Zaulig M, Enderlein D, Romanova J, Leporatti S, Moya S, Donath E 2007,Fusion of enveloped virus nanoparticles with polyelectrolyte-supported lipid membranes for the design of bio/nonbio interfaces. Nano Lett. 2007 Nov;7(11):3540-6.
  17. Ferko B, Kittel C, Romanova J, Sereinig S, Katinger H, Egorov A. Live attenuated influenza virus expressing human interleukin-2 reveals increased immunogenic potential in young and aged hosts. J Virol. 2006 Dec;80(23):11621-7.
  18. Sereinig S, Stukova M, Zabolotnyh N, Ferko B, Kittel C, Romanova J, Vinogradova T, Katinger H, Kiselev O, Egorov A. Influenza virus NS vectors expressing the mycobacterium tuberculosis ESAT-6 protein induce CD4+ Th1 immune response and protect animals against tuberculosis challenge. Clin Vaccine Immunol. 2006 Aug;13(8):898-904.
  19. Stukova MA, Sereinig S, Zabolotnyh NV, Ferko B, Kittel C, Romanova J, Vinogradova TI, Katinger H, Kiselev OI, Egorov A. Vaccine potential of influenza vectors expressing Mycobacterium tuberculosis ESAT-6 protein. Tuberculosis (Edinb). 2006 May-Jul; 86(3-4):236-46.
  20. Rapoport EM, Mochalova LV, Gabius HJ, Romanova J, Bovin NV. Search for additional influenza virus to cell interactions. Glycoconj J. 2006 Feb;23(1-2):115-25. 
  21. Rapoport EM, Mochalova LV, Gabius H-J, Romanova J, Bovin NV. Pattering of Lectins of Vero and MDCK Cells and influenza viruses: the search for additional virus/cell interactions. Handbook of Carbohydrate engineering. Edited by Kevin J.Yarema. Taylor&Francis. 2005.
  22. Kittel C, Ferko B, Kurz M, Voglauer R, Sereinig S, Romanova J, Stiegler G, Katinger H, Egorov A. Related Articles, Generation of an influenza A virus vector expressing biologically active human interleukin-2 from the NS gene segment.J Virol. 2005 Aug;79(16):10672-7.
  23. Stasakova J, Ferko B, Kittel C, Sereinig S, Romanova J, Katinger H, Egorov A. Influenza A mutant viruses with altered NS1 protein function provoke caspase-1 activation in primary human macrophages, resulting in fast apoptosis and release of high levels of interleukins 1beta and 18. J Gen Virol. 2005 Jan;86(Pt 1):185-95.
  24. Katinger D, Mochalova L, Chinarev A, Bovin N, Romanova J. Specificity of neuraminidase activity from influenza viruses isolated in different hosts tested with novel substrates. Arch Virol. 2004 Nov;149(11):2131-40.
  25. Romanova J, Katinger D, Ferko B, Vcelar B, Sereinig S, Kuznetsov O, Stukova M, Erofeeva M, Kiselev O, Katinger H, Egorov A. Live cold-adapted influenza A vaccine produced in Vero cell line. Virus Res. 2004 Jul;103(1-2):187-93.
  26. Kittel C, Sereinig S, Ferko B, Stasakova J, Romanova J, Wolkerstorfer A, Katinger H, Egorov A. Rescue of influenza virus expressing GFP from the NS1 reading frame. Virology. 2004 Jun 20;324(1):67-73.
  27. Katinger D, Romanova J, Ferko B, Fekete H, Egorov A. Effect of a single mutation in neuraminidase on the properties of Influenza B virus isolates. Arch Virol. 2004 Jan;149(1):173-81.
  28. Mochalova L, Gambaryan A, Romanova J, Tuzikov A, Chinarev A, Katinger D, Katinger H, Egorov A, Bovin N. Receptor-binding properties of modern human influenza viruses primarily isolated in Vero and MDCK cells and chicken embryonated eggs. Virology. 2003 Sep 1;313(2):473-80.
  29. Romanova J, Katinger D, Ferko B, Voglauer R, Mochalova L, Bovin N, Lim W, Katinger H, Egorov A. Distinct host range of influenza H3N2 virus isolates in Vero and MDCK cells is determined by cell specific glycosylation pattern. Virology. 2003 Mar 1;307(1):90-7.
  30. Ferko B, Stasakova J, Sereinig S, Romanova J, Katinger D, Niebler B, Katinger H, Egorov A. Hyperattenuated recombinant influenza A virus nonstructural – protein - encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice. J Virol. 2001 Oct;75(19):8899-908.
  31. Grassauer, A., A. Y. Egorov, B. Ferko, I. Romanova, H. Katinger, and T. Muster. 1998. A host restriction-based selection system for influenza haemagglutinin transfectant viruses. J. Gen Virol. 79:1405-1409.
  32. Egorov, A., S. Brandt, S. Sereinig, J. Romanova, B. Ferko, D. Katinger, A. Grassauer, G. Alexandrova, H. Katinger, and T. Muster. 1998. Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J Virol. 72:6437-6441.
  33. Ferko, B., D. Katinger, A. Grassauer, A. Egorov, J. Romanova, B. Niebler, H. Katinger, and T. Muster. 1998. Chimeric influenza virus replicating predominantly in the murine upper respiratory tract induces local immune responses against human immunodeficiency virus type 1 in the genital tract. J Infect Dis. 178:1359-1368.
  34. Klimov, AI, Romanova JR, Egorov AY, Lukashok IV, Kiseleva IV, Alexandrova GI, and Cox NJ. 1995. Nucleotide sequences of the neuraminidase genes of influenza A/Leningrad/134/57 (H2N2) virus and two of its live, attenuated, cold- adapted variants. Virus Genes. 10:95-98.
  35. Romanova, JR, Tannock GA, and Alexandrova GI. 1997. Protective responses in mice to vaccination with multiply administered cold-adapted influenza vaccine reassortants and wild-type viruses. Vaccine. 15:653-658.
  36. Tannock, G. A., J. R. Romanova, and J. A. Paul. 1995. The immunogenicity of reassortants of the cold-adapted influenza A master strain A/Ann Arbor/6/60 is determined by both the genes for cold- adaptation and the haemagglutinin gene. Arch Virol. 140:201-209.
  37. Romanova, J. R., T. A. Ermachenko, G. I. Alexandrova, and G. A. Tannock. 1994. Interference between cold-adapted (ca) influenza A and B vaccine reassortants or between ca reassortants and wild-type strains in eggs and mice. Vaccine. 12:23-27.
  38. Alexandrova, G. I., G. N. Budilovsky, T. A. Koval, F. I. Polezhaev, L. M. Garmashova, Z. Ghendon Yu, Y. R. Romanova, and A. A. Smorodintsev. 1986. Study of live recombinant cold-adapted influenza bivalent vaccine of type A for use in children: an epidemiological control trial. Vaccine. 4:114-118.
  39. Romanova Yu, R., F. I. Polezhaev, M. A. Shneider, and G. I. Aleksandrova. 1986. Interfering activity of epidemic, attenuated and recombinant strains of influenza A virus. Acta Virol. 30:349-352
  40. Alexandrova GI, Polezhaev FI, Budilovsky GN, Garmashova LM, Topuria NA, Egorov AY, Romejko-Gurko YR, Koval TA, Lisovskaya KV, Klimov AI, et al. Recombinant cold-adapted attenuated influenza A vaccines for use in children: reactogenicity and antigenic activity of cold-adapted recombinants and analysis of isolates from the vaccinees. Infect Immun. 1984 Jun;44(3):734-9.


Scientific Editors
  •  Andrej Y. Egorov, MD, DSc, Professor

     CSO, Capricorn Consilium GmbH, Tulln, Austria (ResearcherID)


  •  Irina A. Leneva, DSc 

     Mechnikov Research Institute of Vaccines and Sera, Moscow, Russia (Scopus


  •  Michael Leonidas Chikindas, PhD

     Professor in Microbiology, Rutgers, The State University of New Jersey, New Brunswick, NJ USA 


  •  Maulin Pramod Shah, PhD,

     Chief Scientist and Head of Industrial Wastewater Research Lab, Division of Applied & Environmental Microbiology Lab,

     Enviro Technology Limited, Ankleshwar, India


  • Svetlana A. Sheveleva, DSc,

     Head of the Laboratory, Federal Research Center for Nutrition, Biotechnology and Food Safety, Moscow, Russia 


  • Sergey V. Litvinov, PhD,

     CEO at Aptum Biologics Ltd. United Kingdom




Editors of the English version of the journal
  • Alexander B. Zhivich, PhD, Professor,

     Framingham State University, Framingham, MA, USA  (ResearcherID)   

  • Victor A. Zhivich, MS,

     Program Coordinator at City of Hope Hospital, Duarte, CA USA


Editorial Board
  • Alexey Potekhin, Dsc,

    University of Innsbruck, Austria (Scopus) (ORCID)


  • Galina M. Aleshina, DSc,  

     Institute of Experimental Medicine, St. Petersburg, Russia (Scopus) (ResearcherID)

  • Elena I. Burtseva, MD, DSc, Professor

     Gamaleya Institute of Epidemiology and Microbiology, Moscow, Russia (Scopus)

  • Nikolai V. Bovin, DSc, Professor

     Shemyakin – Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia (Scopus)


  • Misha Lanzat, MD, PhD, physician,

     Veterans Administration Medical Center, Los Angeles, CA, USA

  • Michael Bergmann, MD, PhD, Professor,

     Head of Surgery Department, Medical University of Vienna, Austria (Scopus)


  • Andrey V. Vasin, PhD, DSc, Professor,

    Head of Department of Molecular Biology of Viruses, Smorodintsev Research Institute of Influenza;

    Peter the Great St. Petersburg Polytechnic University (SPBSTU)

    Institute of Biomedical Systems and Biotechnology, Director, St. Petersburg, Russia (Scopus)

  • Jeffrey Almond, PhD, Professor,

    Oxford University, Oxford Martin Visiting Fellow, Oxford, United Kingdom (Scopus)


  • Olga C. Afanasenko, DSc, Professor

    All-Russian Institute of Plant Protection, St. Petersburg, Russia (Scopus) (ResearcherID)


  • Dmitry Y. Vlasov, DSc, Professor

    St. Petersburg State University, Faculty of Biology, St. Petersburg, Russia (Scopus) (ResearcherID) (РИНЦ)

  • Vera G. Arzumanyan, DSc, Professor

    Mechnikov Research Institute for Vaccines and Sera, Moscow, Russia (Scopus) (ResearcherID) (РИНЦ)


  • Natalia E. Gogoleva, PhD

    Research Department for Limnology, University of Innsbruck; Kasan Federal University; Russian Academy of Science (Scopus) (ResearcherID) (ORCID)




Peer Review Policy


A single-blind peer review is mandatory for processing all scientific manuscripts submitted for publication in MIR Journal. This implies that authors do not know who the reviewers of the manuscript are while the reviewers know who the authors are.

  1. Members of the editorial board and leading experts in microbiology, invited as independent reviewers, perform peer reviews. Editor-in-chief choose reviewers for peer review. The peer review process should be finished in the period 4 weeks, though in some cases more time could be allocated at the reviewer’s request.
  2. If the manuscript submitted to the journal is written by members of the MIR Journal Editorial Board, then outside independent reviewers who are not members of the Editorial Board of the journal are invited to perform peer review of this manuscript.
  3. Every manuscript is submitted for review to three different reviewers.
  4. Reviewer has an option to refuse from reviewing the manuscript if any conflict of interests arise that may affect perception or interpretation of the manuscript. As a result of the manuscript review process the reviewer is expected to present the editorial board with one of the following recommendations:
    - to accept the paper for publication in its present state;
    - to accept the paper for publication after the certain revision and correction;
    - to recommend the authors revision of their manuscript in order to address specific concerns before final decision is reached;
    - to recommend further review by other specialist before making the final decision;
    - to reject the manuscript outright.
  5. If the reviewer has recommended any revisions of the manuscript, the editorial staff would ask the authors either to implement the corrections, or to dispute them reasonably. Authors are kindly required to make all the revisions in 1 month and resubmit the revised manuscript within this time frame for final evaluation. The revised manuscript is submitted to reviewers for reevaluation.
  6. We politely request the authors to notify the editor verbally or in writing if the authors decide to refuse from publishing the manuscript. In case the authors fail to do so within 3 months after receiving a copy of the initial review, the editorial board takes the manuscript off the register and notifies the authors accordingly.
  7. If the author and reviewers have insoluble contradictions regarding the manuscript, the editorial board has the right to send the manuscript for additional review. In conflict situations, the decision is made by the editor-in-chief at the editorial board meeting.
  8. The final decision to reject a manuscript is made by the editors according to reviewers’ recommendations. The authors of the manuscript are notified about this decision via e-mail in a timely manner. The editorial board does not accept previously rejected manuscripts for re-evaluation.
  9. Upon the decision to accept the manuscript for publication, the editorial staff notifies the authors of the scheduled date of publication.
  10. Kindly note that positive review does not guarantee the acceptance of the manuscript for publication, as the final decision in all cases lies within the editorial board. In all conflict situations, the decision is made by the editor-in-chief.
  11. Original reviews of submitted manuscripts are kept on file for 5 years.



Publishing Ethics


The Publication Ethics and Publication Malpractice Statement of the journal MIR Journal are based on the Committee on Publication Ethics (COPE) Code of Conduct guidelines available at www.publicationethics.org,  and requirements for peer-reviewed journals developed by the Elsevier Publishing House (according to the international ethical rules for scientific publications)



1.1. Publishing science papers in peer-reviewed journals is a significant contribution to the development of the relevant field of science, and also is an easy way of scientific communication. Therefore, it is important to establish standards for the future ethical conduct of all parties involved in the publication process, namely: the author, the journal editor, the peer reviewer, the publisher and the sponsor for the journal: MIR Journal.

1.2. Publisher has a supporting, investing and nurturing role in the scholarly communication process but is also ultimately responsible for ensuring that best practice is followed in the journal’s publications.

1.3. The publisher is committed to the strict control of scientific materials and recognizes responsibility in all policies especially from the ethical guidelines point of view that are adopted here.


Duties of Editors

2.1. Publication decision – The Editor of the scientific journal MIR Journal is solely and independently responsible for decision to publish or decline the publication of the submitted manuscript. The credibility of the reviewed manuscript and its scientific relevance should determine the decision on acceptance of the manuscript for the publication. Editors may be bound by the policies of the Editorial Board of MIR Journal, limited by current legal requirements in relation to defamation, copyright, legality and plagiarism. The editor may confer with other editors or reviewers in making this decision.

2.2. Decency – An editor should evaluate manuscripts for their intellectual content without regard to race, gender, sexual orientation, religious belief, ethnic origin, citizenship, or political views of the authors.

2.3. Confidentiality – The editor and any editorial staff of MIR Journal should not disclose any information about a submitted manuscript to anyone other than the corresponding author, reviewers, potential reviewers, other editorial advisers, and the publisher, unless it is required by law.

2.4. Disclosure and Conflicts of interest

2.4.1. Unpublished data disclosed in a submitted manuscript should not be used in an editor’s own research without the written consent of the author. Privileged information or ideas obtained during the peer review process should be kept confidential and could not be used for personal advantage.

2.4.2. Editors should recuse themselves (i.e. should ask a co-editor, associate editor or other member of the editorial board instead to review and consider) from reviewing the manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or (possibly) other institutions connected to the manuscripts.

2.5. Control of the publications quality – If an editor has convincing evidence that the statements or conclusions in a published paper are erroneous he/she should coordinate with the publisher to promote the prompt publication of a correction, retraction of the paper, expression of concern, or another note, as appropriate.

2.6. Involvement and cooperation in investigations – The Editor together with the Publisher take appropriate action in the event of ethical claims regarding reviewed manuscripts or published materials. Such measures include interaction with the аuthors of the manuscript and the reasoning of the corresponding complaint or request, but may also involve interaction with relevant third-party organizations and research centers.


Duties of Reviewers

3.1. Contribution to Editorial Board Decisions – Peer review process helps the editor to make editorial decisions and may also assist the author in improving the quality of the manuscript through the communications with the editor. Peer review is a cornerstone of the scientific method and an essential component of formal scholarly communication. The publisher shares the view of many that all scholars who wish to contribute to publications have an obligation to do a fair share of reviewing.

3.2. Promptness – Any selected reviewer who feels that he/she is unqualified to review the manuscript or knows that could not accomplish it in the certain time frame should notify the editor of MIR Journal and excuse himself/herself from the review process.

3.3. Confidentiality – Any manuscripts received for review should be treated as confidential documents. They should not be shown to or discussed with others except as authorized by the editor.

3.4. Standard and objectivity – Reviews should be conducted objectively. Personal criticism of the authors is inappropriate. Reviewers should express their views clearly with supporting arguments.

3.5. Acknowledgement of Sources – Reviewers should identify relevant published papers that have not been cited by the authors. Any previously published statement, observation, derivation, or argument should be accompanied by the corresponding citation. The Reviewer should also draw the editor's attention to any significant similarity or overlap between the manuscript under consideration and any other published work within the scope of the reviewer's scientific competence.

3.6. Disclosure and Conflict of Interest

3.6.1. Any and all unpublished data that is disclosed in a submitted manuscript should not be used in a reviewer’s own research without the written consent of the authors. All information and/or ideas obtained through the peer review process should be kept confidential and should not be used for personal advantage.

3.6.2. Reviewers should not be involved in the peer review process of the  manuscripts in which they have conflicts of interest resulting from competitive, collaborative, or other relationships or connections with any of the authors, companies, or institutions connected to the manuscripts.


Duties of Authors

4.1. Requirements for manuscripts

4.1.1. Authors of manuscripts describing original research should provide credible results of their research as well as an objective discussion of its significance. All the essential and supplemental data should be presented accurately. The manuscript should contain sufficient experimental details and bibliographic references for the successful reproduction of the results. False or knowingly wrong statements are perceived as unethical behavior and are unacceptable.

4.1.2. Reviews and scientific articles should also be accurate and objective; editor’s point of view in editorial papers should be clearly indicated.

4.2. Data Access and Storage – Authors may be asked to provide the raw data in connection with a manuscript for editorial review, and should be prepared to provide public access to such data (consistent with the ALPSP-STM Statement on Data and Databases), if possible, and should in any event be prepared to retain such data for a reasonable time after publication.

4.3. Originality and Plagiarism

4.3.1. The authors should ensure that they have submitted an entirely original manuscript, and if the authors have used data and/or statements published elsewhere, they have been appropriately cited and/or quoted.

4.3.2. Plagiarism takes many forms, from “passing off” paper written by other scientists as the author’s own paper, to copying or paraphrasing substantial parts of another paper (without the corresponding attribution), to claiming results from research conducted by others. Plagiarism in all its forms constitutes unethical publishing behavior and is unacceptable.

4.4. Multiple, Redundant or Concurrent Publications

4.4.1. In general an author should not publish manuscripts describing essentially the same research as original publications in more than one journal. Submitting the same manuscript to more than one journal concurrently constitutes unethical publishing behavior and is unacceptable.

4.4.2. In general, an author should not submit a previously published paper for consideration in another journal.

4.4.3. Publication of certain types of articles (e.g., clinical guidelines, translations) in more than one journal is sometimes acceptable, provided that certain conditions are met. The authors and editors of the journals involved should agree on the secondary publication, which should present the same data and interpretation as in the original publication. The secondary publication should have the reference on the original publication. Further detail on acceptable forms of secondary publications can be found at www.icmje.org.

4.5. Acknowledgement of Sources

The contributions of others should always be recognized. Authors should cite publications that are relevant to the research presented in the manuscript. Data obtained privately, for example, in the course of conversation, correspondence or in the course of discussion with third parties, should not be used or presented without the explicit written permission of the original source. Information obtained from confidential sources e.g. in the course of evaluating manuscripts or awarding grants, should not be used without the clear written permission of authors related to confidential sources.

4.6. Authorship of the Paper

4.6.1. Authorship should be limited to those who have made a significant contribution to the development of the conception, design, execution, or interpretation of results of the research study described in the manuscript. All those who have made significant contributions should be listed as co-authors. In cases where other participants have made a significant contribution in a particular direction of a research project, they should be listed in Acknowledgement section as persons who have contributed to this research project.

4.6.2. The corresponding author should ensure that all those who have made a significant contribution to the project are included as co-authors in the manuscript and that there are no co-authors who did not make a significant contribution to the project; that all co-authors have seen and approved the final version of the paper and have agreed to its submission for publication.

4.7. Hazards and Human or Animal Subjects

4.7.1. If the research project involves the use of chemicals, procedures or equipment that present any unusual hazards, the author must clearly identify these hazards in the manuscript.

4.7.2. If the research project involves the use of animal or human subjects, the author/authors should ensure that the manuscript contains a statement that all procedures were performed in compliance with corresponding laws and institutional guidelines and that the appropriate institutional committee(s) have approved them. The manuscript should contain a statement that informed consent has been obtained from all the humans who are the subjects of research. The privacy rights of human beings must always be respected.

4.8. Disclosure and Conflicts of Interest

4.8.1. All authors should disclose in the manuscript any financial or other conflicts of interest that might influence the results or their interpretation in the manuscript. All sources of financial support for the project should be disclosed.

4.8.2. Examples of potential conflicts of interest which should be disclosed include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Potential conflicts of interest should be disclosed at the earliest possible stage.

4.9. Significant errors in published papers – When an author discovers a significant error or inaccuracy in a published paper, it is the author’s obligation to promptly notify the editor of MIR Journal and cooperate with publisher to retract or correct the paper. If the editor or the publisher learn from a third party that a published paper contains a significant error, they communicate it to the author, and it is the obligation of the author to promptly retract or correct the paper.

5. Retraction Policy

MIR Journal follows ScienceOpen retraction policy. Please follow the link for details: https://about.scienceopen.com/scienceopens-retraction-policy/


Data Policy


Authors are encouraged to make available the research data that support their publications but are not required to do so. The consent or refusal of the authors to provide access to research data should not affect the decision on the article publication.


Definition of research data

This policy applies to the research data that would be required to verify the results of research reported in articles published in the MIR Journal. Research data include the data produced by the authors (“primary data”) and the data from other sources that are analyzed by authors in their study (“secondary data”). Research data includes any recorded factual material that is used to produce the results in digital and non-digital form. This includes tabular data, code, images, audio, documents, video, maps, raw and/or processed data.


Definition of exceptions

The data that are not a subject to public disclosure may be delivered as follows: deposited in science data repositories with limited access or preliminary anonymized. An author can also publicly disclose metadata and/or description of the access method to the data as requested by other scholars.


Data repositories

The preferred method for sharing research data is via data repositories. Please visit https://repositoryfinder.datacite.org/ website for help in finding research data repositories.


Data citation

The Editorial Board of MIR Journal welcomes access to research data under the Creative Commons Licenses. Editorial Board of MIR Journal does not insist on the mandatory use of Creative Commons License in cases when the data are deposited in the repository of the third party. The Publisher of the MIR Journal does not assert any copyrights for the data submitted by the authors together with the article.  

Questions and compliance letters regarding the data citation and licensing should be directed to the MIR Journal (editor@mir-journal.org).



Author Agreement


Open Access Publishing Agreement

By submitting my manuscript to the journal Network Medicine published by REPO4EU (hereafter the ‘Publisher’) and managed by ScienceOpen, I herewith grant permission to the Publisher to publish my article upon editorial acceptance under the following publishing agreement.

I hereby confirm that this is my original work and that

  • I own sole copyright in this work
  • And/or I have obtained permission from all other Authors to execute this Agreement on their behalf if necessary

And that the work

  • Has never been published before.

I understand that in granting this consent I am granting to the Publisher the Rights to publish under a Creative Commons CC-BY 4.0 license the Contribution in the English language in digital form; moral rights will be retained by the original Author/s and copyright will be held by the Author.

I agree to this Publishing Agreement, consent to execution and delivery of the Publishing Agreement electronically and agree that confirming my consent electronically during the manuscript submission process with an electronic signature shall be given the same legal force as a handwritten signature.

Terms of Use

  1. The Contribution will be made Open Access under the terms of the Creative Commons Attribution License (CC-BY 4.0 License) which permits use, distribution and reproduction in any medium, provided that the Contribution is properly cited.
  2. The Journal (and Publisher) reserves the right to require changes to the Contribution as a condition of its acceptance. The Journal (and Publisher) reserves the right, notwithstanding acceptance, not to publish the Contribution if for any reason such publication would in the reasonable judgment of the Journal (and Publisher), result in legal liability or violation of journal ethical practices. If the Journal (or Publisher) decides not to publish the Contribution, the Author is free to submit the Contribution to any other journal from any other publisher.
  3. As above, the final Contribution will be made Open Access under the terms of the CC-BY license. Reproduction, posting, transmission or other distribution or use of the final Contribution in whole or in part in any medium by the Author as permitted by this Agreement requires a citation to the Journal suitable in form and content as follows: (Title of Contribution, Author, Journal Title and Volume/lssue, Digital Object Identifier (DOI), Date). Links to the final published Contribution should be provided following the guidance below on best practice.

Retained Rights

The Author retains all proprietary rights in addition to copyright, such as patent rights in any process, procedure or article of manufacture described in the Contribution.

Author's Representations

The Author(s) certify that they have participated sufficiently in the intellectual content, conception and design of this work or the analysis and interpretation of the data (when applicable), as well as the writing of the manuscript, to take public responsibility for it and have agreed to have their name listed as a contributor. The Author(s) believe the manuscript represents valid work. Neither this manuscript nor one with substantially similar content under their authorship has been published or is being considered for publication elsewhere, with the exception of online posting as a preprint. If requested by the editors, the Author(s) will provide the data/information or will cooperate fully in obtaining and providing the data/information on which the manuscript is based, for examination by the editors or their assignees. Financial interests, direct or indirect, that exist or may be perceived to exist for individual contributors in connection with the content of this paper have been disclosed in a "Conflicts of Interest" statement in the manuscript. Sources of outside support of the project are named in the Acknowledgements section.

Use of Information

The Author(s) acknowledges that, during the term of this Agreement and thereafter (for as long as necessary), the Publisher and the Journal may process the Author’s personal data, including storing or transferring data outside of the country of the Contributor’s residence, in order to communicate with the Author(s) and that the Publisher has a legitimate interest in processing the Author(s)’ personal data. By entering into this Agreement, the Author(s) agree to the processing of personal data (and, where applicable, confirms that the Author has obtained the permission from all other authors to process their personal data). The Publisher and the Journal shall comply with all applicable laws, statutes and regulations relating to data protection and privacy and shall process such personal data.


Human Rights Policy


The journal MIR Journal relies on the principles and endeavors of WMA Declaration of Helsinki https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/ to ensure compliance with ethical and data collection standards for research involving human subjects. When presenting the results of experimental research involving human subjects, the authors should indicate whether the procedures performed adhered to the ethical standards prescribed in the Declaration of Helsinki.

All research involving human subjects should be carried out in compliance with the principles of the Helsinki Declaration on informed consent and carry out the research in strict accordance with those principles as set forth below (Articles 25-32 of the Helsinki Declaration are given):

  1. Participation by individuals capable of giving informed consent as subjects in medical research must be voluntary. Although, it may be appropriate to consult family members or community leaders, no individual capable of giving informed consent may be enrolled in a research study unless he/she freely agrees.
  2. In medical research involving human subjects capable of giving informed consent, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail, post-study provisions and any other relevant aspects of the study.  The potential subject must be informed of his right to refuse to participate in the study or to withdraw his consent to participate at any time without reprisal. Special attention should be given to the specific information needs of individual potential subjects as well as the methods used to deliver the information.

After ensuring that the potential subject has understood the information, the physician or another appropriately qualified individual must then seek the potential subject's freely given informed consent, preferably in writing.  If the consent cannot be expressed in writing, verbal consent must be formally documented and witnessed.

All medical subjects should be given the option of being informed about the general outcome and results of the study.

  1. When seeking informed consent for participation in a research study, the physician must be particularly cautious when the potential subject is in a dependent relationship with the physician or may consent under duress. In such situations, the informed consent must be sought by an appropriately qualified individual who is completely independent of this relationship.
  2. For a potential research subject who is incapable of giving informed consent, the physician must seek informed consent from his legally authorized representative. These individuals must not be included in a research study that has no likelihood of benefit for them unless it is intended to promote the health of the group represented by the potential subject, the research cannot instead be performed with persons capable of providing informed consent, and the research entails minimal risk and burden.
  3. When a potential research subject who is deemed incapable of giving informed consent is able to give assent to decisions about participation in research, the physician must seek that assent in addition to the consent of the legally authorized representative. The potential subject's dissent should be respected.
  4. Research involving subjects who are physically or mentally incapable of giving consent, for example, unconscious patients, may be done only if the physical or mental condition that prevents giving informed consent is a necessary characteristic of the research group. In such circumstances the physician must seek informed consent from the legally authorized representative. If no such representative is available and if the research cannot be delayed, the study may proceed without informed consent provided that the specific reasons for involving subjects with a condition that renders them unable to give informed consent have been stated in the research protocol and the study has been approved by a research ethics committee. Consent to remain in the research must be obtained as soon as possible from the subject or a legally authorized representative.
  5. The physician must fully inform the patient which aspects of their care are related to the research. The refusal of a patient to participate in a study or the patient's decision to withdraw from the study should never adversely affect the patient-physician relationship.
  6. For medical research using identifiable human material or data, such as research on material or data contained in biobanks or similar repositories, physicians must seek informed consent for its collection, storage and/or reuse. There may be exceptions where consent would be impossible or impractical to obtain for such research. In such situations, the research may be done only after consideration and approval of a research ethics committee.

If the study was conducted without adherence to the principles of the Declaration of Helsinki, the authors should justify the chosen approach to the study and guarantee that the ethics committee of the organization in which the study was conducted approved the chosen approach.


Copyright Notice


The authors who publish papers in MIR Journal agree to the following:

  1. The authors retain the copyright for the paper and grant the journal the right to first publish the paper under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International Public License (CC BY-NC-SA), which permits unrestricted use, distribution, and reproduction in any medium, as long as the material is not used for commercial purposes, provided that the original author and source are cited.
  2. The authors reserve the right to enter into separate contractual agreements regarding the non-exclusive distribution of the version of the paper published here (for example, placing it in the institution's repository, publication in a book), with the reference to its original publication in this journal.
  3. Authors have the right to post their manuscript on the Internet (for example in open-access repository of electronic preprints, in an institute repository or personal website) before and during the review process by this journal, as this may lead to productive discussion and more references to this work (See The Effect of Open Access).


Publication Fee


Publication in MIR Journal is free of charge for all the authors.

The journal doesn't have any Article submission charges.

The journal doesn't have any Article processing charges.




Information about the legal entity

The  Publisher of the Microbiology Independent Research journal is the company 



All questions please address to editor@mir-journal.org





Call for papers


Dear Colleagues,

We invite you to publish your scientific articles in the Microbiology Independent Research Journal (MIR Journal) at www.mir-journal.org (ISSN 2500-2236).

MIR Journal is an international platform for scientists and medical professionals across academia, industry, and healthcare. We publish original research articles and scientific reviews, including short reports, hypotheses, and comments on the latest achievements and discoveries in:

- virology

- bacteriology

- molecular biology

- mycology

- synthetic biology

- antibacterial and antiviral drug discovery.

Published on the ScienceOpen platform (Germany/USA) in Austria, MIR Journal is indexed in DOAJ and the international scientific databases CAS (Chemical Abstracts Service) and EBSCO, as well as in Google Scholar, CrossRef, Ulrichsweb, Scilit, OpenAIRE, and CORE.

Benefits of publishing in MIR Journal

1. No publication fee

2. Rigorous single-blind peer review for all submitted articles

3. Rapid publication of accepted manuscripts

4. Acceptance of articles in both English and Russian

5. Open access to the full text of all articles on the Internet


MIR Journal Editorial Board


Collection Information

Latest Issue